Review highlights strong safety and effectiveness of mRNA vaccines
· News-MedicalmRNA platforms for future disease prevention and treatment
mRNA vaccines deliver genetic instructions to human cells to manufacture harmless viral proteins that train the immune system to recognise and fight the real virus. This process is temporary and ends once the body has learned to defend itself; it does not change a person's DNA. The first FDA-approved mRNA vaccines were introduced during the COVID-19 pandemic, building upon decades of research to quickly scale up approval, production, and distribution.
Beyond COVID-19, the authors emphasize the versatility of the mRNA platform. Efforts are underway to develop vaccines against influenza, RSV, and other infectious diseases, as well as personalized cancer vaccines and RNA-based therapeutics. This breadth of potential applications signals a future in which mRNA technology could be tailored to individual patients and specific disease threats, offering rapid, flexible, and effective tools for public health.
"As the world continues to confront evolving infectious threats, our review underscores the need for sustained innovation, robust surveillance, and true global collaboration to maximize the life-saving benefits of this groundbreaking technology. mRNA vaccines have already transformed how we respond to emerging diseases, and with ongoing innovation and rigorous safety monitoring, they can drive progress in preventive medicine and cancer treatment for years to come," said co-author Dr Manish Sadarangani of the University of British Columbia and BC Children's Hospital Research Institute (Canada).
Expanding global access and equity
The authors also highlight that improvements in mRNA vaccine formulation and distribution enhance access and equity, as higher-temperature storage extends shelf life and lowers costs, broadening distribution.
Because mRNA vaccines are based on a common platform and can be adjusted to new targets much faster than other vaccine platforms, the manufacturing process is scalable and tightly controlled to keep the RNA pure and effective. Across the supply chain, vaccines are kept in specialized freezers and temperature-controlled settings, and newer storage options, such as higher-temperature storage and freeze-drying, are helping more vaccines reach remote places quickly and reduce waste. This combination helped speed up COVID-19 vaccine development and distribution.
"Expanding manufacturing capacity and ensuring equitable access in low- and middle-income countries is essential if mRNA vaccines are to fulfill their promise as a global public good. By investing in technology transfer, local production, and robust regulatory systems, we can shorten supply chains, reduce costs, and ensure that people everywhere benefit from safe, effective vaccines beyond pandemics," said co-author Dr Robin Shattock of Imperial College London (UK).
The authors note the importance of ongoing post-licensure safety monitoring and long-term follow-up to study post-marketing real-world performance of existing licensed mRNA vaccines. They also emphasize the importance of documenting all instances of side effects, no matter how rare, as some signals might be missed or misinterpreted in real-world observational studies. Additional study limitations include that the review's findings come from many different countries and programs, so results may vary by population, vaccine product, and how safety data are collected. Finally, the ongoing evolution of viruses means that effectiveness might change with new variants.
Source:
Journal reference: